
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
U and I Financial Corporation (QX) | USOTC:UNIF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.95 | 3.15 | 4.05 | 0.00 | 20:51:50 |
This is the final approval step for the schemes of arrangement which will now proceed to implementation to effect the Unilife Group's redomiciliation in the United States of America. Implementation is expected to occur on 27 January 2010 and no further action is required by shareholders and option holders of the Company.
The Schemes will become effective once a copy of the Court orders have been lodged with the Australian Securities and Investments Commission, which the Company intends to do 15 January 2010 (Scheme Effective Date).
Trading in Unilife securities on ASX
As previously advised, shareholders may elect to receive either:
-- one share of Unilife Corporation common stock for every six shares held in the Company as at the record date for the Schemes -- these shares will be tradeable on NASDAQ assuming the NASDAQ listing application is successful; or -- one Unilife Corporation CHESS Depositary Interests (CDI) for every share held in the Company (subject to rounding) -- the CDIs will tradeable on ASX.
The Company's existing shares will be suspended from quotation on ASX with effect from the close of business on the Scheme Effective Date and Unilife Corporation CDIs are expected to commence trading on ASX on a deferred settlement basis on 18 January 2010.
The ASX ticker code for Unilife Corporation will be "UNS."
Shareholders who trade Unilife Corporation CDIs before receiving confirmation of their allocation of CDIs (ie. between the date deferred settlement trading commences on 18 January 2010 and receipt of a holding statement representing their new holding of CDIs) do so at their own risk. Shareholders can ascertain their entitlement to Unilife Corporation securities by calling Computershare on 1300 729 064 (within Australia) + 61 3 9415 4677 (outside Australia) at any time after the record date for the Share Scheme, being 22 January 2010.
Update on NASDAQ listing
The Company is now in the process of completing the final steps necessary for the listing of Unilife Corporation on NASDAQ. Subject to the Form 10 registration statement being declared effective by the SEC and Unilife Corporation's NASDAQ listing application being approved, Unilife Corporation expects its common stock to commence trading on NASDAQ on or around 10 February 2010.
The reserved NASDAQ ticker code for Unilife Corporation is "UNIS."
Comment from Unilife Chief Executive Officer, Alan Shortall
"Unilife has now received the final green light needed to complete our redomiciliation from Australia to the United States of America and move to finalising our listing on NASDAQ.
"During this transition period, which will result in Unilife Corporation becoming the trading entity for the Unilife Group, shareholders will need to be conscious of upcoming changes to our ticker codes. On 18 January 2010, our ASX code will change from 'UNI' to 'UNS' and Unilife Corporation CDIs will commence trading on ASX on a deferred settlement basis. From 2 February 2010, CDI trading should commence on a normal T+3 settlement basis.
"For those shareholders electing to retain their Unilife shares on the ASX as CDIs, there will be little apparent change apart from our Australian ticker code. Shareholders choosing to transfer their holdings to shares of Unilife Corporation common stock that will be tradeable on NASDAQ (subject to the application to list on NASDAQ being approved) will have their shares consolidated on a six to one basis. Following the NASDAQ listing, should shareholders wish to trade their shares of Unilife Corporation common stock, they may choose to either convert it back to CDIs or appoint a qualified broker with the capacity to trade in Unilife Corporation common stock on NASDAQ on their behalf."
Timetable to implementation
The Company would also like to take this opportunity to set out the timetable for completion of the redomiciliation:
Event Date ------------------------------------------------------ ----------------- Federal Court hearing for approval of the Schemes 14 January 2010 ------------------------------------------------------ ----------------- Effective Date of the Schemes 15 January 2010 ------------------------------------------------------ ----------------- Suspension of the Company's shares from trading on ASX 15 January 2010 ------------------------------------------------------ ----------------- Unilife Corporation CDIs commence trading on ASX on a deferred settlement basis 18 January 2010 ------------------------------------------------------ ----------------- Record Date for the Schemes 22 January 2010 ------------------------------------------------------ ----------------- Implementation Date for the Schemes 27 January 2010 ------------------------------------------------------ ----------------- Despatch of holding statements and transmittal letters 1 February 2010 ------------------------------------------------------ ----------------- CDIs commence trading on normal T+3 basis 2 February 2010 ------------------------------------------------------ ----------------- Expected commencement date for listing on NASDAQ 10 February 2010 (subject to SEC review of Form 10 and approval of NASDAQ listing application) ------------------------------------------------------ ----------------- All dates and times are indicative only and are subject to change. All dates and times are Australian Eastern Daylight Time
About Unilife
Unilife Medical Solutions Ltd. is an ISO 13485 certified company that designs, develops and supplies innovative safety medical devices. Listed on the Australian Securities Exchange (ASX: UNI) since 2002, Unilife has FDA-registered manufacturing facilities in the US State of Pennsylvania and a proprietary portfolio of clinical and prefilled safety syringes designed for use within healthcare and pharmaceutical markets.
Shareholder / Analyst Enquiries: Australia Jeff Carter Phone: + 61 2 8346 6500 United States Stuart Fine Phone: + 1 908 469 1788
1 Year U and I Financial (QX) Chart |
1 Month U and I Financial (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions